Ikeda M, Sugiyama K, Tanaka T, Tanaka K, Sekihara H, Shimotohno K, Kato N
Virology Division, National Cancer Center Research Institute, Tokyo, Japan.
Biochem Biophys Res Commun. 1998 Apr 17;245(2):549-53. doi: 10.1006/bbrc.1998.8481.
We found that bovine lactoferrin (bLF), a milk protein belonging to the iron transporter family, effectively prevented hepatitis C virus (HCV) infection in cultured human hepatocytes (PH5CH8), a cell line susceptible to HCV infection and supportive of HCV replication. Because preincubation of HCV with bLF was required to prevent the infection of HCV to the cells, and preincubation of bLF with the cells showed no inhibitory effect on HCV infection, we demonstrated that the anti-HCV activity of bLF was due to the interaction of bLF with HCV, but not due to the interaction of bLF with the cells. We further found that human lactoferrin also had anti-HCV activity, but bovine transferrin, the other member of the iron transporter family, did not have anti-HCV activity. Our findings suggest that lactoferrin is one of candidates for an anti-HCV reagent that will be well-tolerated and effective in the treatment of patients with chronic hepatitis.
我们发现,牛乳铁蛋白(bLF)是一种属于铁转运蛋白家族的乳蛋白,它能有效预防丙型肝炎病毒(HCV)在培养的人肝细胞(PH5CH8)中的感染,PH5CH8是一种对HCV感染敏感且支持HCV复制的细胞系。由于需要将HCV与bLF预孵育以防止HCV感染细胞,而将bLF与细胞预孵育对HCV感染无抑制作用,我们证明bLF的抗HCV活性是由于bLF与HCV的相互作用,而非bLF与细胞的相互作用。我们进一步发现,人乳铁蛋白也具有抗HCV活性,但铁转运蛋白家族的另一个成员牛转铁蛋白不具有抗HCV活性。我们的研究结果表明,乳铁蛋白是抗HCV试剂的候选药物之一,这种试剂在慢性肝炎患者的治疗中耐受性良好且有效。